Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Xenon Pharmaceuticals’ dense biotech disclosures is no small task; a single 10-K can bury crucial details on epilepsy trial progress, cash runway, and royalty obligations deep inside footnotes. If you’ve ever wondered how to locate "Xenon Pharmaceuticals insider trading Form 4 transactions" or confirm the next XEN1101 milestone payment without skimming hundreds of pages, you’re not alone.
Stock Titan solves that problem. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, 8-K material event, and Form 4 insider filing the instant they hit EDGAR and delivers plain-English takeaways. Think of it as "understanding Xenon Pharmaceuticals SEC documents with AI"—R&D burn rates, Phase 3 enrollment updates, or executive stock option grants are surfaced in seconds. Real-time alerts keep you ahead when "Xenon Pharmaceuticals Form 4 insider transactions" post mid-session.
- Xenon Pharmaceuticals quarterly earnings report 10-Q filing with pipeline spend broken down
- Xenon Pharmaceuticals annual report 10-K simplified—risk factors, cash position, dilution tables
- Xenon Pharmaceuticals executive stock transactions Form 4 and related proxy statement executive compensation
- Xenon Pharmaceuticals 8-K material events explained—FDA feedback, trial pauses, public offerings
- Xenon Pharmaceuticals earnings report filing analysis powered by AI
Whether you’re tracking "Xenon Pharmaceuticals insider trading Form 4 transactions real-time" before a data readout or comparing sequential R&D spend, our platform condenses complex biotech language into actionable insights. Save hours, reduce uncertainty, and focus on what matters: the science and the numbers.
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.
Xenon Pharmaceuticals (XENE) filed a Form 144 reporting a proposed sale of 25,000 common shares through Canaccord Genuity Corp. on the NASDAQ with an aggregate market value of $1,004,117. The filer states the shares were acquired and paid for on 10/01/2025 by exercising options issued by the company and paid in cash. The notice lists 77,105,799 shares outstanding and reports no securities sold by the filer in the past three months. Some standard filer identification fields (CIK/Contact) are blank in the provided text.
Xenon Pharmaceuticals Inc. (XENE) filed a Form 144 notice reporting a proposed sale of 2,548 common shares through Morgan Stanley Wealth Management Canada Inc. on the NASDAQ with an aggregate market value of $94,490. The shares were acquired on 09/19/2025 by exercise of options from the issuer and were paid via a net exercise on the same date. The filing shows 77,105,799 shares outstanding and reports no securities sold in the past three months by the selling person. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Xenon Pharmaceuticals (XENE) received a Schedule 13G/A disclosing that Wellington-affiliated filers report beneficial ownership of 2,174,761 common shares, representing 2.83% of the class. The filing shows no sole voting or dispositive power and shared voting power of 2,146,462, with shared dispositive power of 2,174,761, indicating the positions are managed jointly by Wellington entities.
The filing states these securities are owned of record by Wellington clients and held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. No client is identified as owning more than 5% of the class.
Xenon Pharmaceuticals Inc. reported results for the quarter ended June 30, 2025. Management states it held $624.8 million of cash, cash equivalents and marketable securities and expects these resources to fund operations for at least the next 12 months. Total assets were $674.3 million and total liabilities were $40.3 million, leaving shareholders' equity of $634.0 million. The company recorded a net loss of $149.8 million for the six months ended June 30, 2025 (net loss of $84.7 million for the three months), and an accumulated deficit of $1,049.2 million.
Research and development spending rose to $136.2 million for the six months, driven by azetukalner program costs (direct costs of $74.9 million). Collaboration revenue of $7.5 million was recognized related to a Neurocrine milestone; NBI-921355 is in Phase 1. Clinically, X-TOLE2 patient recruitment is complete with topline data anticipated in early 2026, and multiple Phase 3 trials (X-TOLE3, X-ACKT, X-NOVA2/3, X-CEED) are underway or enrolling.
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
Form 3 overview: On 25 June 2025, Xenon Pharmaceuticals Inc. (XENE) filed an Initial Statement of Beneficial Ownership (Form 3) on behalf of newly disclosed officer Darren S. Cline, Chief Commercial Officer. The filing reports the event date as 23 June 2025 and confirms Mr. Cline’s Section 16 insider status.
Key disclosure: Both Table I (non-derivative holdings) and Table II (derivative holdings) state "No securities are beneficially owned,” meaning Mr. Cline presently holds zero shares or options of Xenon. No amendments, joint filings, or indirect ownership structures are noted. The document is therefore a procedural compliance filing rather than a transaction or compensation event and contains no financial metrics, option grants, or purchase details.
For investors, the absence of insider ownership could be interpreted as a lack of immediate equity alignment, but the filing primarily signals timely regulatory compliance following Mr. Cline’s appointment.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
